HASBROUCK HEIGHTS, N.J., Oct. 5, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that a new formal statistical analysis of double-blind clinical trial data from pooled subjects in Phase 2 clinical trials for NX-1207, the Company’s investigational treatment for BPH, confirmed that clinically significant benefits of a single NX-1207 treatment extend to 12 months or longer.
